Business Strategies & Innovations Committee

Chair: Perry Karsen, Chief Executive Officer, Celgene Cellular Therapeutics, Inc.
Staff Contact: Amy Finan, Senior Vice President, Business Development, afinan(at)bio.org 

Description: The committee provides guidance to BIO management on the organization’s business strategy regarding current and future non-dues revenue opportunities for the organization.  This source of revenues is important to continuing BIO’s support of membership services and the organization’s advocacy mission.  The Business Strategies & Innovations Committee of the BIO Board of Directors is organized structurally under the Full Board of Directors because its purview is cross-cutting in nature and not limited to one specific Section Governing Board. 

Members:
Adam Monroe, President-Americas, Novozymes
Arlene Morris, Chief Executive Officer, Syndax Pharmaceuticals, Inc.
Daniel Junius, President & CEO, ImmunoGen, Inc.
David Stack, President & CEO, Pacira Pharmaceuticals, Inc.
Douglas Doerfler, President & CEO, MaxCyte, Inc.
Emer Leahy, President & CEO,  PsychoGenics, Inc.
H. Thomas Watkins, Chair Emeritus,BIO
John Orwin, Chief Executive Officer, Relypsa, Inc.
Kristine Peterson, Chief Executive Officer, Valeritas, Inc.
Maxine Gowen, Chief Executive Officer, Trevena, Inc.
Paul Hastings, President & CEO, OncoMed Pharmaceuticals, Inc.
R. John Glasspool, VP, New Therapies & Market Development, Baxter Healthcare Corporation 
Thomas Mathers, Chief Executive Officer, CoLucid Pharmaceuticals, Inc.
Timothy Walbert, Chairman, President & CEO, Horizon Pharma, Inc.